Literature DB >> 11803508

Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection.

Mark D King1, David A Reznik, Christine M O'Daniels, Nina M Larsen, Dawn Osterholt, Henry M Blumberg.   

Abstract

Oral warts are a manifestation of human papillomavirus infection that have been noted infrequently in persons with human immunodeficiency virus (HIV). A nested case-control study was conducted to assess rates of and risk factors for oral warts among a cohort of HIV-seropositive patients. From 1997 through 1999, 56 patients with oral warts were identified among 2194 HIV-positive patients attending an urban oral health center (prevalence, 2.6%). Incident cases of oral warts were significantly more likely to have been diagnosed in 1999 than they were in 1997-1998 (P=.001). Multivariate analysis indicated that the risk of oral warts was associated with a >/=1-log(10) decrease in HIV RNA level in the 6 months before diagnosis of oral warts (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.08-5.11) and with serologic evidence of chronic or previous infection with hepatitis B virus (OR, 2.66; 95% CI, 1.31-5.41). The incidence of oral warts in HIV-seropositive patients appears to be increasing in the era of highly active antiretroviral therapy. Oral warts were associated with reductions in virus load, which suggests that this may in part be related to immune reconstitution.

Entities:  

Mesh:

Year:  2002        PMID: 11803508     DOI: 10.1086/338637

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

Authors:  M Israr; D Mitchell; S Alam; D Dinello; J J Kishel; C Meyers
Journal:  HIV Med       Date:  2010-08-15       Impact factor: 3.180

2.  Diminished responsiveness to human β-defensin-3 and decreased TLR1 expression on monocytes and mDCs from HIV-1-infected patients.

Authors:  Nicholas T Funderburg; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2012-07-18       Impact factor: 4.962

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.

Authors:  Mohd Israr; Danielle Mitchell; Samina Alam; Donald Dinello; Joseph J Kishel; Craig Meyers
Journal:  Antivir Ther       Date:  2010

5.  Viral infections associated with oral cancers and diseases in the context of HIV: a workshop report.

Authors:  D J Speicher; V Ramirez-Amador; D P Dittmer; J Webster-Cyriaque; M T Goodman; A-B Moscicki
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

Review 6.  Overview of the oral HIV/AIDS Research Alliance Program.

Authors:  C H Shiboski; J Y Webster-Cyriaque; M Ghannoum; J S Greenspan; D Dittmer
Journal:  Adv Dent Res       Date:  2011-04

7.  Update from the 4th Edition of the World Health Organization of Head and Neck Tumours: Tumours of the Oral Cavity and Mobile Tongue.

Authors:  Susan Müller
Journal:  Head Neck Pathol       Date:  2017-02-28

8.  Highly tissue substructure-specific effects of human papilloma virus in mucosa of HIV-infected patients revealed by laser-dissection microscopy-assisted gene expression profiling.

Authors:  Nicole Baumgarth; Richard Szubin; Greg M Dolganov; Mitchell R Watnik; Deborah Greenspan; Maria Da Costa; Joel M Palefsky; Richard Jordan; Mario Roederer; John S Greenspan
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 9.  Oral HPV complications in HIV-infected patients.

Authors:  Jennifer E Cameron; Michael E Hagensee
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

10.  Development and validation of a HPV-32 specific PCR assay.

Authors:  Nicholas R Herrel; Nadia L Johnson; Jennifer E Cameron; Janet Leigh; Michael E Hagensee
Journal:  Virol J       Date:  2009-06-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.